Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



AstraZeneca PLC: a Leading FTSE Dividend Stock with Substantial Growth Potential

January 12, 2025
AstraZeneca PLC (NASDAQ:AZN) has emerged as one of the top FTSE dividend stocks to buy now. With its strong financial performance and promising pipeline of innovative drugs, the company offers attractive returns for investors.

Despite the challenges posed by the global pandemic, AstraZeneca has consistently delivered solid financial results. In its latest quarterly report, the company reported a 15% increase in revenue and a 28% increase in earnings per share. This reflects the success of its key drugs, such as Tagrisso for lung cancer and Farxiga for type 2 diabetes.

What sets AstraZeneca apart from its competitors is its robust pipeline of potential blockbuster drugs. The company has a strong focus on oncology, respiratory diseases, and cardiovascular health. Its recent acquisition of Alexion Pharmaceuticals further strengthens its portfolio with innovative therapies for rare diseases.

Investors looking for long-term growth and stable dividends should consider AstraZeneca. The company has a track record of consistently increasing its dividend payout, making it an attractive option for income investors. In fact, AstraZeneca's dividend yield is currently higher than the average for FTSE 100 stocks.

To make informed investment decisions, it is recommended to seek professional advice from industry experts. Stocks Prognosis provides accurate forecasts and expert analysis on the movement of AstraZeneca PLC shares. Their insights can help investors optimize their investment strategy and maximize returns.

Disclaimer: The contents of this article are for informational purposes only and should not be considered as financial advice. Investing involves risks, and it is important to conduct thorough research and consult with professionals before making any investment decisions.
If you want to leave a comment, then you need Login or Register





Other data for AZN

Related data

AZNSeptember 3, 2025ASTRAZENECA PLC Hits QuantWave Forecast, Generating 16.24% Profit  ~2 min.

ASTRAZENECA PLC has successfully reached the price target forecasted by QuantWave on July 11, 2025. The forecast indicated a long position with a price of 70.64 $....


AZNSeptember 3, 2025ASTRAZENECA PLC Hits 11.81% Profit Target as Forecasted by QuantWave  ~1 min.

ASTRAZENECA PLC's stock has successfully reached the price target forecasted by QuantWave, resulting in a profit of 11.81%. The forecast signal was given on 2025-08-01 when the stock was trading at 73....


AZNSeptember 3, 2025ASTRAZENECA PLC Stock Hits QuantWave Price Target with Profit of 19.38%  ~1 min.

On July 17, 2025, QuantWave, the automated forecasting platform, issued a long signal for ASTRAZENECA PLC stock when it was trading at 68.78 $....


AZNSeptember 3, 2025ASTRAZENECA PLC Stock Hits Price Target Forecast with 17.98% Profit  ~1 min.

On July 16, 2025, QuantWave's automated forecasting platform issued a signal for ASTRAZENECA PLC, predicting a long position with the stock trading at $69.6....


AZNSeptember 3, 2025ASTRAZENECA PLC Hits Price Target Forecast with 13.12% Profit  ~2 min.

On July 31, 2025, QuantWave, an automated forecasting platform, issued a long signal for ASTRAZENECA PLC when the stock was trading at $72.59....


AZNSeptember 3, 2025ASTRAZENECA PLC Hits QuantWave Forecast Target with 11.64% Profit  ~2 min.

ASTRAZENECA PLC has successfully reached the price target forecasted by QuantWave, resulting in a profit of 11.64%. The forecast signal was issued on August 8, 2025, with the stock priced at $73....


AZNSeptember 3, 2025ASTRAZENECA PLC Stock Hits Price Target with 12.34% Profit: QuantWave Forecast Success  ~1 min.

ASTRAZENECA PLC stock has successfully achieved the price target forecast set by QuantWave, resulting in a profit of 12.34%. The forecast signal was generated on August 6, 2025, with a price of $73....


AZNSeptember 3, 2025QuantWave Successfully Hits Price Target Forecast for AstraZeneca PLC, Yielding 15.25% Profit  ~2 min.

On July 14, 2025, QuantWave, the automated forecasting platform, issued a signal to go long on AstraZeneca PLC with a price of $71.24....


AZNAugust 25, 2025AstraZeneca's Breakthrough Study on Advanced Biliary Tract Cancer  ~1 min.

AstraZeneca PLC has recently announced groundbreaking results from their new study on advanced biliary tract cancer, showing promising potential for a new treatment option in cancer care....


AZNAugust 22, 2025ASTRAZENECA PLC Hits Price Target Forecast with 20.55% Profit  ~1 min.

On January 23, 2025, QuantWave issued a long signal for ASTRAZENECA PLC with a price of 67.17 $. The forecast proved to be accurate as the stock reached the target price of 80....


AZNJanuary 2, 2025AstraZeneca PLC AZN's Innovative Approach Leading the Way in Pharmaceutical Industry  ~2 min.

AstraZeneca PLC (AZN) continues to make waves in the pharmaceutical industry with its innovative approach to drug development....


AZNJanuary 2, 2025Recent Developments in AstraZeneca PLC: A Promising Future for Investors  ~2 min.

AstraZeneca PLC, a renowned multinational pharmaceutical company, has been making significant strides in the healthcare industry....


AZNDecember 12, 2024Why Astrazeneca AZN is a Top Value Stock for the Long-Term  ~2 min.

AstraZeneca PLC (LON:AZN) has recently been identified as a top value stock for long-term investors....


AZNJanuary 1, 2025Stocks Prognosis: Is AstraZeneca PLC AZN Set to Become a U.K. Dividend Champion by 2024?  ~2 min.

AstraZeneca PLC, a leading global pharmaceutical company, is garnering attention from investors as it seeks to establish itself as a U.K. Dividend Champion by 2024....


AZNMarch 16, 2025AstraZeneca's Experimental Blood Pressure Drug Could Become a Blockbuster  ~2 min.

AstraZeneca PLC (NASDAQ:AZN) has recently developed an experimental drug for treating high blood pressure, which experts believe has a strong potential to become a blockbuster in the pharmaceutical market....